Skip to main content
. 2021 Feb 6;5(1):e14–e23. doi: 10.1055/s-0040-1721782

Table 4. Hemostatic markers in the two study groups during the period.

Time ( n int / n ctr ) Intervention Controls p- Value
F 1+2 (pmol/L) Baseline (22/21) 210.80 ± 185.96 196.69 ± 60.30 0.11
6 mo (17/19) 190.88 ± 55.41 235.86 ± 84.04
12 mo (22/21) 203.14 ± 57.60 256.19 ± 222.25
D-dimer (ng/mL) Baseline (22/21) 349.38 ± 147.48 355.62 ± 140.54 0.26
6 mo (18/20) 449.34 ± 263.07 458.10 ± 251.50
12 mo (22/21) 479.24 ± 311.65 356.87 ± 126.94
Fibrinogen (g/L) Baseline (22/21) 3.38 ± 0.62 3.13 ± 0.52 0.70
6 mo (17/19) 3.36 ± 0.69 3.36 ± 0.56
12 mo (21/21) 3.43 ± 0.83 3.12 ± 0.54
FVIIAg (%) Baseline (21/21) 100.45 ± 16.75 100.99 ± 14.65 0.046
6 mo (16/20) 108.65 ± 21.69 103.54 ± 17.23
12 mo (21/21) 110.35 ± 20.21 104.82 ± 14.98
Total TFPI (ng/mL) Baseline (21/21) 63.47 ± 11.94 61.94 ± 14.49 0.28
6 mo (16/20) 66.59 ± 15.07 63.16 ± 14.54
12 mo (21/20) 65.40 ± 17.05 62.46 ± 14.08
Free TFPI (ng/mL) Baseline (21/21) 8.36 ± 2.75 7.93 ± 2.64 0.71
6 mo (16/18) 10.31 ± 3.45 10.24 ± 3.09
12 mo (21/20) 10.72 ± 4.65 9.94 ± 3.55
vWF (pg/mL) Baseline (21/21) 114.73 ± 21.80 105.45 ± 18.67 0.26
6 mo (16/19) 129.24 ± 26.85 126.75 ± 23.79
12 mo (21/20) 125.75 ± 26.68 118.08 ± 18.36

Note: Values are means ± standard deviation. The p -values are obtained from the fixed group effect from the ANCOVA mixed model with baseline values as covariates. FVIIAg is measured as % of normal plasma pool. “Time ( n int / n ctr )” represents the time of the sampling and the number of samples available for biomarker analysis from the intervention ( n int ) and control group ( n ctr ).

Abbreviations: F 1+2 , prothrombin fragment 1 + 2; FVIIAg, coagulation factor VII antigen; TFPI, tissue factor pathway inhibitor; VWF, von Willebrand factor.

HHS Vulnerability Disclosure